The Antiplatelet Effect of Clopidogrel Decreases with Patient Age

Angiology

Volumn 67, Issue 10, 2016, Pages 902-908

  Xhelili, Endri ^a   Eichelberger, Beate ^a   Kopp, Christoph W ^a   Koppensteiner, Renate ^a   Panzer, Simon ^a   Gremmel, Thomas ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

age; clopidogrel; flow cytometry; platelet activation

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; GLYCOPROTEIN IB ALPHA; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; PADGEM PROTEIN; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; TICLOPIDINE;

ADULT; AGE; AGED; ANGIOPLASTY; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING PARAMETERS; COMBINATION DRUG THERAPY; DRUG EFFECT; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

ADENOSINE DIPHOSPHATE; AGE FACTORS; AGED; ASPIRIN; DRUG THERAPY, COMBINATION; FLOW CYTOMETRY; HUMANS; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84990853792     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319716631249     Document Type: Article

References (35)

1. Michelson AD,. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov. 2010; 9 (2): 154-169.
2. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK,. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345 (7): 494-502.
3. Cattaneo M,. P2Y12 receptor antagonists: a rapidly expanding group of antiplatelet agents. Eur Heart J. 2006; 27 (9): 1010-1012.
4. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW,. Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy. Thromb Res. 2009; 124 (5): 588-591.
5. Gremmel T, Müller M, Steiner S, et al. Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. Nephrol Dial Transpl. 2013; 28 (8): 2116-2122.
6. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW,. Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation. Transl Res. 2013; 161 (5): 421-429.
7. Gremmel T, Panzer S,. Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrel. Thromb Haemost. 2011; 106 (2): 211-218.
8. Gremmel T, Kopp CW, Seidinger D, et al. Differential impact of cytochrome 2C9 allelic variants on clopidogrel-mediated platelet inhibition determined by five different platelet function tests. Int J Cardiol. 2013; 166 (1): 126-131.
9. Gremmel T, Durstberger M, Eichelberger B, Koppensteiner R, Panzer S,. Calcium-channel blockers attenuate the antiplatelet effect of clopidogrel. Cardiovasc Ther. 2015; 33 (5): 264-269.
10. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008; 51 (3): 256-260.
11. Serebruany V, Pokov I, Kuliczkowski W, Chesebro J, Badimon J,. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost. 2008; 100 (1): 76-82.
12. Erlinge D, Varenhorst C, Braun OO, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol. 2008; 52 (24): 1968-1977.
13. Gremmel T, Kopp CW, Moertl D, et al. Influence of cytochrome 2C19 allelic variants on on-treatment platelet reactivity evaluated by five different platelet function tests. Thromb Res. 2012; 129 (5): 616-622.
14. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW,. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart. 2010; 96 (3): 186-189.
15. Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013; 62 (24): 2261-2273.
16. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol. 2009; 53 (10): 849-856.
17. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay a 12-month follow-up. Circulation. 2009; 119 (2): 237-242.
18. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW,. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. J Thromb Haemost. 2010; 8 (1): 37-42.
19. Silvain J, Cayla G, Hulot JS, et al. High on-thienopyridine platelet reactivity in elderly coronary patients: The SENIOR-PLATELET study. Eur Heart J. 2012; 33 (10): 1241-1250.
20. Cuisset T, Quilici J, Grosdidier C, et al. Comparison of platelet reactivity and clopidogrel response in patients ≤75 years versus >75 years undergoing percutaneous coronary intervention for nonST-segment elevation acute coronary syndrome. Am J Cardiol. 2011; 108 (10): 1411-1416.
21. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW,. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost. 2009; 101 (2): 333-339.
22. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW,. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent. Thromb Res. 2011; 128 (4): 352-357.
23. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW,. In vivo and protease-activated receptor-1-mediated platelet activation but not response to antiplatelet therapy predict two-year outcomes after peripheral angioplasty with stent implantation. Thromb Haemost. 2014; 111 (3): 474-482.
24. Gremmel T, Kopp CW, Seidinger D, et al. The formation of monocyte-platelet aggregates is independent of on-treatment residual agonists'-inducible platelet reactivity. Atherosclerosis. 2009; 207 (2): 608-613.
25. Thomas MR, Wijeyeratne YD, May JA, Johnson A, Heptinstall S, Fox SC,. A platelet P-selectin test predicts adverse cardiovascular events in patients with acute coronary syndromes treated with aspirin and clopidogrel. Platelets. 2014; 25 (8): 612-618.
26. Gremmel T, Frelinger AL III, Michelson AD,. Platelet Physiology. Semin Thromb Hemost. 2016; 42 (3): 191-204.
27. Gremmel T, Koppensteiner R, Kaider A, Eichelberger B, Mannhalter C, Panzer S,. Impact of variables of the P-selectin-P-selectin glycoprotein ligand-1 axis on leukocyte-platelet interactions in cardiovascular disease. Thromb Haemost. 2015; 113 (4): 806-812.
28. Lukasik M, Dworacki G, Kufel-Grabowska J, Watala C, Kozubski W,. Upregulation of CD40 ligand and enhanced monocyte-platelet aggregate formation are associated with worse clinical outcome after ischaemic stroke. Thromb Haemost. 2012; 107 (2): 346-355.
29. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI,. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: Studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 2001; 104 (13): 1533-1537.
30. Shattil SJ, Hoxie JA, Cunningham M, Brass LF,. Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. J Biol Chem. 1985; 260 (20): 11107-11114.
31. Michelson AD, Barnard MR, Krueger LA, Frelinger AL III, Furman MI,. Evaluation of platelet function by flow cytometry. Methods. 2000; 21 (3): 259-270.
32. Gremmel T, Koppensteiner R, Panzer S,. Comparison of aggregometry with flow cytometry for the assessment of agonists'-induced platelet reactivity in patients on dual antiplatelet therapy. PLoS One. 2015; 10 (6): e0129666.
33. Tanaka E,. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther. 1998; 23 (4): 247-255.
34. Abernethy DR, Greenblatt DJ,. Impairment of lidocaine clearance in elderly male subjects. J Cardiovasc Pharm. 1983; 5 (6): 1093-1096.
35. Frelinger AL III, Bhatt DL, Lee RD, et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol. 2013; 61 (8): 872-879.